From the publishers of The New England Journal of Medicine
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.
Some content may require paid access to the site. Subscribe or
purchase a seven-day site pass for the full text of
all our clinical perspectives on medical journal articles, guidelines, and news.
Studies presented at the 2010 Retrovirus Conference add to our knowledge about the neurological effects of HIV infection and the potentially beneficial role of early effective ART.
HIV infection does not seem to increase the risk for or severity of 2009 H1N1 influenza, according to data presented at the 2010 Retrovirus Conference.
The few data presented on this topic at the 2010 Retrovirus Conference revealed important differences between the sexes and potential benefits to early, time-limited treatment.
An expert describes the studies that treating physicians will likely find most interesting.
In a randomized study, standard combination therapy was preferable to a quadruple-NRTI regimen in terms of both virologic control and adverse effects.
Data presented at IAS 2009 highlighted new approaches to PI therapy for patients with virologic suppression, including simplifying ritonavir-boosted atazanavir to unboosted atazanavir and trying to sustain suppression using darunavir without nucleosides. Success rates differed among these strategies.
One large study presented at IAS 2009 supported an association between abacavir and cardiovascular risk, but another did not.
Early data presented at IAS 2009 are encouraging.
The combination of nevirapine + tenofovir + FTC (or 3TC) is safe and effective in treatment-naive patients, according to data presented at IAS 2009.
In a study conducted in Botswana (and reported at IAS 2009), the rate of mother-to-child transmission was only 1% among breast-feeding women who received ART through 6 months postpartum.